Literature DB >> 27737872

Dalteparin-sodium induced drug fever in a neonate.

Dirk Wackernagel1, Sami Obaya1, Per Nydert2.   

Abstract

Drug fever caused by dalteparin-sodium (DS), a low-molecular-weight derivative of heparin, is neither listed in the official drug information and nor published as a case report until today. A preterm infant, born at 26 weeks of gestation, developed fever 2 days after starting a treatment with DS for an intracardial thrombus. The fever reverses soon after changing the treatment to unfractionated heparin and reappeared after reintroduction of DS. Once again, after discontinuing DS, the infant regained normothermia. Bacterial and viral infections, tissue damage, impaired liver or kidney function, preservative agents and comedications could be ruled out as fever origin. By using the Naranjo adverse drug reaction (ADR) probability scale and the Liverpool ADR causality assessment tool, this case can be classified as 'probable ADR' and 'definite ADR'. This is the first case report of a drug fever caused by the low-molecular-weight heparin DS in a preterm infant. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27737872      PMCID: PMC5073694          DOI: 10.1136/bcr-2016-217621

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  9 in total

1.  Unexplained high fever in an elderly patient treated with clonidine, duloxetine, and atorvastatin.

Authors:  Theodoros Kelesidis; Iosif Kelesidis
Journal:  Clin Ther       Date:  2009-12       Impact factor: 3.393

Review 2.  Drug fever.

Authors:  D H Johnson; B A Cunha
Journal:  Infect Dis Clin North Am       Date:  1996-03       Impact factor: 5.982

Review 3.  Continuous heparin infusion to prevent thrombosis and catheter occlusion in neonates with peripherally placed percutaneous central venous catheters.

Authors:  Prakeshkumar S Shah; Vibhuti S Shah
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

4.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

5.  Multicenter dose-finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism.

Authors:  S H O'Brien; R Kulkarni; A Wallace; F Hamblin; S Burr; N A Goldenberg
Journal:  J Thromb Haemost       Date:  2014-10-18       Impact factor: 5.824

6.  Furosemide-associated fever.

Authors:  H W Clegg; D A Riopel
Journal:  J Pediatr       Date:  1995-05       Impact factor: 4.406

7.  Drug Fever: a descriptive cohort study from the French national pharmacovigilance database.

Authors:  Dominique Vodovar; Christine LeBeller; Bruno Mégarbane; Agnes Lillo-Le-Louet; Thomas Hanslik
Journal:  Drug Saf       Date:  2012-09-01       Impact factor: 5.606

Review 8.  Drug fever.

Authors:  Ruchi A Patel; Jason C Gallagher
Journal:  Pharmacotherapy       Date:  2010-01       Impact factor: 4.705

9.  Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool.

Authors:  Ruairi M Gallagher; Jamie J Kirkham; Jennifer R Mason; Kim A Bird; Paula R Williamson; Anthony J Nunn; Mark A Turner; Rosalind L Smyth; Munir Pirmohamed
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.